Evidence map›Paper›PMID 38127314›Full record

ArticleThe Journal of general physiology2024

Elucidating molecular mechanisms of protoxin-II state-specific binding to the human NaV1.7 channel.

Khoa Ngo, Diego Lopez Mateos, Yanxiao Han, Kyle C Rouen, Surl-Hee Ahn, Heike Wulff, Colleen E Clancy, Vladimir Yarov-Yarovoy, Igor Vorobyov

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of general physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Harnessing AlphaFold to reveal hERG channel conformational state secrets.bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Khoa Ngo *Biophysics Graduate Group, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-7454-2924
Diego Lopez Mateos *Biophysics Graduate Group, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-8627-7208
Yanxiao HanDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-1684-6073
Kyle C RouenBiophysics Graduate Group, University of California, Davis, Davis, CA, USA.ORCID 0000-0001-8684-0614
Surl-Hee AhnDepartment of Chemical Engineering, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-3422-805X
Heike WulffDepartment of Pharmacology, University of California, Davis, Davis, CA, USA.ORCID 0000-0003-4437-5763
Colleen E ClancyDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, USA.ORCID 0000-0001-6849-4885
Vladimir Yarov-YarovoyDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-2325-4834
Igor VorobyovDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-4767-5297
University of California, Davis · USPrecision for Medicine (United States) · US

Funding

Functional Interactions of Cardiac Ion ChannelsR01HL085844 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN · 2007 to 2025
$7.3M
Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Development of the Predictive NeuroCardiovascular SimulatorOT2OD026580 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, GRANDI, ELEONORA · 2018 to 2021
$5.7M
In silico Safety PharmacologyR01HL128537 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, SANTANA, LUIS F · 2016 to 2024
$5.7M
Predictive multiscale in silico cardio-pharmacologyU01HL126273 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E · 2015 to 2019
$3.8M
Breakthrough Molecular Dynamics Research via an Anton2 SupercomputerR01GM116961 · NIGMS · CARNEGIE-MELLON UNIVERSITY · PI BLOOD, PHILIP D. · 2016 to 2023
$3.0M
Multi-Scale Modeling of Vascular Signaling UnitsR01HL152681 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CLANCY, COLLEEN E, SANTANA, LUIS F · 2020 to 2023
$2.4M
Digital Twins from the Atom to the RhythmR01HL174001 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COLLEEN E CLANCY, Luis F Santana · 2024 to 2026
$2.4M
UC Davis Training Program in Chemical BiologyT32GM136597 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHEILA Sue DAVID, Marie C. Heffern · 2021 to 2026
$1.7M
NHLBI NIH HHS R01 HL085844NHLBI NIH HHS R01 HL128537NHLBI NIH HHS R01HL128537NHLBI NIH HHS R01 HL152681NHLBI NIH HHS R01 HL174001NHLBI NIH HHS T32 HL086350NHLBI NIH HHS U01 HL126273NIGMS NIH HHS 5T32GM136597-02NIGMS NIH HHS R01 GM116961NIGMS NIH HHS T32 GM136597NIH HHS OT2 OD026580NIH HHS OT2OD026580
6 · The paper itself

Abstract

Human voltage-gated sodium (hNaV) channels are responsible for initiating and propagating action potentials in excitable cells, and mutations have been associated with numerous cardiac and neurological disorders. hNaV1.7 channels are expressed in peripheral neurons and are promising targets for pain therapy. The tarantula venom peptide protoxin-II (PTx2) has high selectivity for hNaV1.7 and is a valuable scaffold for designing novel therapeutics to treat pain. Here, we used computational modeling to study the molecular mechanisms of the state-dependent binding of PTx2 to hNaV1.7 voltage-sensing domains (VSDs). Using Rosetta structural modeling methods, we constructed atomistic models of the hNaV1.7 VSD II and IV in the activated and deactivated states with docked PTx2. We then performed microsecond-long all-atom molecular dynamics (MD) simulations of the systems in hydrated lipid bilayers. Our simulations revealed that PTx2 binds most favorably to the deactivated VSD II and activated VSD IV. These state-specific interactions are mediated primarily by PTx2's residues R22, K26, K27, K28, and W30 with VSD and the surrounding membrane lipids. Our work revealed important protein-protein and protein-lipid contacts that contribute to high-affinity state-dependent toxin interaction with the channel. The workflow presented will prove useful for designing novel peptides with improved selectivity and potency for more effective and safe treatment of pain.

Indexed as

NAV1.7 Voltage-Gated Sodium ChannelPeptidesSpider VenomsAction PotentialsHumansInterneuronsMolecular Dynamics SimulationPainNAV1.7 Voltage-Gated Sodium ChannelPeptidesprotoxin II, Thrixopelma pruriensSCN9A protein, humanSpider Venoms

Identifiers

PMID38127314
PMCPMC10737443
OpenAlexW4390049287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.